post-stroke cognitive impairment
Conditions
Interventions
cTBS stimulation group:Using a TMS-60D magnetic field stimulator manufactured by Maxx (Zhengzhou) Medical Technology Co., Ltd., the patient was seated comfortably with minimal head movement. The resea
interplexus frequency of 5 Hz, interplexus count of 200, stimulation time of 40 s
total number of pulses: 600
intensity: 80% of the activity threshold. Treatment was administered once daily for 9 consecutive days.
cTBS sham stimulation group:The researcher held a circular coil and placed it perpendicular to the scalp at the top of the subject's head. The instrument and other stimulation parameters were the same
Sponsors
Guangdong Provincial People's Hospital
Eligibility
Sex/Gender
All
Age
40 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. First stroke confirmed by computed tomography (CT) scan or magnetic resonance imaging (MRI), which occurred less than 12 months; 2. Based on cognitive function assessment, which evaluates four cognitive domains including executive/attention, memory, language, and visual spatial function, cognitive function declines from baseline and at least one cognitive domain is impaired, with a clear temporal relationship between cognitive impairment and stroke; 3. Aged 40-80 years; 4. Education: primary school (grade 6) or above; 5. Mini-Mental State Examination (MMSE) score of >=15; Montreal Cognitive Assessment (MoCA) score less than 26; 6. The Hamilton depression rating scale (HAMD) score of <17; 7. Not on drugs for cognitive improvement; 8. Have a stable and reliable caregiver; 9. Written consent form signed by the patient.
Exclusion criteria
Exclusion criteria: 1. Non-unilateral or infratentorial lesions; 2. Previous history of stroke, brain tumor, brain trauma or other neurological diseases; 3. Cognitive decline caused by other reasons, such as AD, PD, frontotemporal dementia, Lewy body dementia, VitB12 deficiency, hypothyroidism, etc.; 4. Severe alcoholism, drug dependence, and other conditions that affect cognitive assessment; 5. Taking drugs that have a negative effect on cognitive function, such as anticholinergics, antipsychotics, antiepileptic drugs, etc.; 6. Those who cannot undergo MRI examination; 7. Patients with contraindications to TMS, such as intracranial metal implants, brain tumors, and patients with increased intracranial pressure; 8. Patients with mental illness, including schizophrenia, bipolar disorder, major depression, delirium, etc. that meet DSM-IV criteria; 9. There are uncorrectable visual and auditory impairments that cannot complete the scale and other related tests; 10. Patients with aphasia; 11. Those who cannot be followed.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the Alzheimer’s Disease Assessment Scale, cognitive subscale, ADAS-cog;Lymphoid pathway clearance efficiency;neuroflament light, NfL;glial fibrillary acidic protein, GFAP; | — |
Secondary
| Measure | Time frame |
|---|---|
| Montreal Cognitive Assessment, MoCA;Mini-Mental State Examination, MMSE;Digit Span Test;Stroop Test;Trail Making Test;Verbal Category Fluency Test, VCFT;Clock Drawing Test, CDT;Modified Barthel Index, MBI;Stroke-Specific Quality of Life, SS-QoL;Hamilton Depression Rating Scale (HAMD); | — |
Countries
China
Contacts
Public ContactXu Guangqing
Guangdong Provincial People's Hospital
Outcome results
None listed